Search

CN-122012304-A - Active factor of bifidobacterium animalis subspecies JD37 with cell repair function

CN122012304ACN 122012304 ACN122012304 ACN 122012304ACN-122012304-A

Abstract

The invention relates to the technical field of microorganisms, and particularly discloses an application of bifidobacterium animalis subspecies JD37 (Bifidobacterium animalis subsp.lactis JD 37) and an active factor thereof in cell repair. The strain is preserved in China Center for Type Culture Collection (CCTCC) at the 6 th month of 2025, and the preservation number is CCTCC No. M20251293. The invention firstly separates JD37 strain from breast milk source microbial community, and the secreted active factors comprise exosomes. In vitro cell experiments prove that the JD37 active factor can obviously promote the mobility of fibroblasts, reduce the expression level of inflammatory factors TNF-alpha and CRP and activate an autophagy pathway. The active factor can be made into lyophilized powder, exosome injection or functional food, and can be used for repairing skin wound, repairing skin and treating metabolic syndrome.

Inventors

  • WANG GUOMIN
  • DENG ZHAOQUN

Assignees

  • 海口必火投资有限公司
  • 博吉弘康(嘉兴)生物医药有限公司

Dates

Publication Date
20260512
Application Date
20251202

Claims (9)

  1. 1. The bifidobacterium animalis subspecies JD37 is characterized in that the bifidobacterium animalis subspecies JD37 is Bifidobacterium animalis subsp.lactis JD37, and is preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of CCTCC No. M20251293.
  2. 2. An active factor of bifidobacterium animalis subspecies JD37 as claimed in claim 1 comprising exosomes having particle sizes in the range 60-80 nm.
  3. 3. The active factor according to claim 2, wherein the exosomes are extracted by ultracentrifugation, specifically comprising removing cell debris from the bacterial fermentation broth by centrifugation at10,000Xg, filtering the supernatant with a 0.22 μm filter, and collecting the exosome precipitate by ultracentrifugation at 100,000Xg 120 min.
  4. 4. A pharmaceutical composition comprising an active agent according to claims 2-3, characterized by comprising a pharmaceutically acceptable carrier.
  5. 5. Use of a pharmaceutical composition according to claim 4 for the preparation of a formulation for promoting cell repair, including skin fibroblast migration, skin repair.
  6. 6. Use of a pharmaceutical composition according to claim 4 for the preparation of a formulation for reducing inflammatory factors TNF- α and CRP.
  7. 7. A freeze-dried powder preparation is characterized in that the preparation is prepared by mixing the strain of claim 1 and a freeze-drying protective agent according to a volume ratio of 1:1, pre-freezing at-70 ℃, and freeze-drying.
  8. 8. The lyophilized powder formulation of claim 7, wherein the lyoprotectant comprises maltodextrin, sucrose.
  9. 9. The lyophilized powder formulation according to claim 7, wherein the mass fraction ratio of lyoprotectant is maltodextrin to sucrose is 1:1.

Description

Active factor of bifidobacterium animalis subspecies JD37 with cell repair function Technical Field The invention relates to the technical field of microorganisms, in particular to an active factor of bifidobacterium animalis subspecies JD37 with cell repair function. Background Cell repair disorders are the core pathological mechanisms of skin trauma, muscle atrophy and metabolic diseases. The existing clinically applied growth factor preparations (such as EGF and bFGF) have the problems of short half-life and high cost, and stem cell therapy has ethical contention and tumorigenic risks. Bifidobacteria are recognized as safe probiotics, and metabolites thereof have been confirmed to have the functions of regulating immunity, reducing cholesterol and the like, but research on direct cell repair effect has not been conducted intensively. In the prior art, CN 118844633B discloses that bifidobacterium animalis subspecies CP-9 and HN019 can improve intestinal barrier through competitive inhibition of pathogenic bacteria adhesion, CN 106535908A discloses that strain LMG P-28149 can reduce adipocyte infiltration through regulating PPARgamma pathway, and CN 120549985A discloses that strain F1-3-2 can improve sarcopenia through downregulating muscle atrophy marker MuRF-1. However, the active ingredients of these strains have not been clearly isolated and verification of direct repair mechanisms for cell migration, autophagy, etc. is lacking. The invention separates animal bifidobacterium subspecies JD37 from breast milk microbiome for the first time, and proves that the secreted exosome can promote cell repair, thus providing a new way for developing novel cell repair preparations. Disclosure of Invention The invention firstly provides an animal Bifidobacterium subspecies JD37, wherein the animal Bifidobacterium subspecies JD37 is Bifidobacterium analytisu.lactisJD 37 which is preserved in China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC No. M20251293. The invention also provides an active factor of the bifidobacterium animalis subspecies JD37, which comprises exosomes, wherein the particle size of the exosomes is 60-80 nm. In certain embodiments, wherein the exosomes are extracted by ultracentrifugation, specifically comprising removing cell debris from the bacterial fermentation broth by centrifugation at 10,000Xg, filtering the supernatant with a 0.22 μm filter, and collecting the exosome pellet by ultracentrifugation at 100,000Xg 120 min. The invention also provides a pharmaceutical composition containing the active factor, and the pharmaceutical composition contains a pharmaceutically acceptable carrier. The invention also provides application of the pharmaceutical composition in preparation of a preparation for promoting cell repair, wherein the cell repair comprises skin fibroblast migration and skin repair. The invention also provides application of the pharmaceutical composition in preparation of preparations for reducing inflammatory factors TNF-alpha and CRP. The invention also provides a freeze-dried powder preparation, which is prepared by mixing the strain and a freeze-drying protective agent according to the volume ratio of 1:1, pre-freezing at-70 ℃, and freeze-drying. In certain embodiments, the lyoprotectant comprises maltodextrin, sucrose. In certain embodiments, the mass fraction ratio of lyoprotectant is maltodextrin to sucrose is 1:1. Compared with the prior art, the invention has at least the following beneficial effects: (1) Efficient cell repair, the JD37 exosome can promote fibroblast migration and is beneficial to skin repair. (2) Multichannel modulation by simultaneous activation of the autophagy pathway (LC 3-II/LC 3-I) and inhibition of inflammatory factors (TNF- α). (3) The application forms are various, and the preparation can be prepared into injection (local repair), fermented milk (oral whole body regulation) or microcapsule (targeted delivery). Preservation description Bifidobacterium animalis subsp.lactisjd37 was isolated from a sample of healthy breast milk and was deposited at China Center for Type Culture Collection (CCTCC) at 2025, 6, and was designated as Bifidobacterium animalis subsp.lactisjd37 under the accession number of CCTCC NO: M20251293 at the address of Hubei Wuhan, university of Wuhan. Drawings FIG. 1 is a drawing of a JD37 exosome electron microscope. FIG. 2 is a graph showing the particle size distribution of the JD37 exosomes. Detailed Description In order to make the technical problems, technical solutions and advantages to be solved by the present invention more apparent, the following detailed description will be made with reference to specific embodiments. Example 1 isolation of Strain JD37 and identification of the Material of (1) Sample Source healthy breast milk sample (from Beijing city women and young health care Hospital) (2) The separation method comprises the following steps: Diluting the sample with PBS, coatin